Zai Lab Limited announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase 3 pivotal trial of Tumor Treating Fields in patients with pancreatic cancer. PANOVA-3 is a global, open-label, randomized Phase 3 trial evaluating the efficacy of Tumor Treating Fields administered concomitantly with gemcitabine and nab-paclitaxel as front-line treatment for patients with unresectable, locally advanced pancreatic cancer. The trial is expected to enroll approximately 556 patients.

The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, resectability rate, and toxicity.